Context Therapeutics (CNTX) Return on Assets (2021 - 2026)
Context Therapeutics (CNTX) posted Return on Assets of 0.01% for Q1 2026, down 55.81% sequentially from 0.01% in Q4 2025, and little changed YoY from 0.01% in Q1 2025.
Context Therapeutics (CNTX) Return on Assets (2021 - 2026) Analysis & Trends
Context Therapeutics has reported Return on Assets for 6 years, with the latest figure at 0.01% in Q1 2026.
- Quarterly Return on Assets changed 0.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
- Return on Assets eased to 0.01% in Q1 2026 per CNTX's latest filing, from 0.01% in the prior quarter.
- Over five years, Return on Assets peaked at 0.0% in Q2 2022 and troughed at 0.03% in Q1 2024.
- A 5-year average of 0.01% and a median of 0.01% in 2025 frame the typical range for Return on Assets.
- The sharpest annual moves came in 2023 and 2024: Return on Assets declined 2 bps in 2023, then rose 2 bps in 2024.
- Over 5 years, Return on Assets stood at 0.01% in 2022, then plunged by 256 bps to 0.02% in 2023, then surged by 72 bps to 0.01% in 2024, then rose by 10 bps to 0.01% in 2025, then tumbled by 56 bps to 0.01% in 2026.
- According to Business Quant data, Return on Assets over the past three periods registered 0.01%, 0.01%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.01% |
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.01% |
| Jun 30, 2024 | -0.01% |
| Mar 31, 2024 | -0.03% |
| Dec 31, 2023 | -0.02% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | -0.01% |
| Mar 31, 2023 | -0.01% |
| Dec 31, 2022 | -0.01% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.00% |